The present application is concerned with methods for increasing the bioavailability and/or activity of agents and in particular allows selective targeting of an agent to, or via, the liver or allows the liver to be bypassed. By selecting which of saturated fatty acids (SFA), short chain fatty acids (SCFA), medium chain fatty acids (MCFA), polyunsaturated fatty acids (PUFA), monounsaturated fatty acids (MUFAs) and long chain fatty acids (LCFA) are present in a composition and which predominates it is possible to substantially boost bioavailability and also to selectively target whether an agent is delivered to, or via, the liver or alternatively bypasses the liver. The approach is a versatile platform technology which may be applied to agents in general helping achieve better and more efficient delivery. In one preferred embodiment particular carotenoids are employed to further influence whether delivery is to, or via, the liver, or bypasses the liver.

Oral compositions comprising cinnamaldehyde, and methods or improving circulation and improving circulation by administering such compositions, are described. Methods and uses are describe that include the administration of an effective amount of the oral compositions to improve circulation and increasing nerve sensitization, while also resulting in improved balance, and reduced pain, numbness, and/or tingling in the hands and feet, as well as reduced restlessness, fatigue, and tiredness of the legs.

One aim of the present invention is to treat or prevent chronic kidney disease. Provided is a treatment or prophylactic pharmaceutical composition for chronic kidney disease, that contains an SGLTl-inhibiting compound or a pharmaceutically acceptable salt thereof.

Some embodiments disclosed herein relate to a composition containing an effective amount of dietary nutrients. In some embodiments, ingestion of the composition provides one or more of the following benefits, or others, improved functioning of an environmentally stressed eye, increased tear flow from the lacrimal glands, improved quality of the lipid secretion from the meibomian glands (e.g., to improve tear breakup time), and augmented DHA fatty acid in the retina damaged by blue light. In some embodiments, the composition is configured to scavenge free radicals in the eye to prevent premature degradation of the visual functions.

According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

The present invention is directed to the treatment of idiopathic pulmonary fibrosis with (a) a phosphodiesterase 4 inhibitor or (b) a phosphodiesterase 4 inhibitor and a second active pharmaceutical ingredient.

The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.

The present disclosure relates to a nanoemulsion composition of oxygen gas sustained release and method for preparing the same, and provides a nanoemulsion composition of oxygen gas sustained release and method for preparing the same, including a water phase part containing water, and an oil phase part dispersed in the water phase part and made of nanoparticle containing a perfluorocarbon compound, wherein the oil phase part contains oxygen gas, and the oxygen gas is released in sustained release. According to the present disclosure, there are advantages of preventing hair loss or promoting hair growth by increasing the amount of oxygen gas supplied to the hair bulb and the oxygen release time from the hair bulb.

Formulations with enhanced SN-38 solubility and oral absorption. In one embodiment, a formulation or a pharmaceutical composition comprises (a) 7-Ethyl-10-hydroxy-camptothecin (SN-38); and (b) a mixture of pharmaceutically acceptable excipients comprising (i) N-Methylpyrrolidone; and (ii) Vitamin E TPGS or a copolymer, the copolymer being 50/50 poly(lactic-co-glycolic acid), or 75/25 poly(lactic-co-glycolic acid) (PLGA); with the provision that if the VitE TPGS is present, the mixture of the excipients further comprises a polymer selected from the group consisting of Hydroxypropyl cellulose, Hydroxypropyl methylcellulose, VP/VAc copolymer 60/40, poloxamer 407, and Lauroyl Macrogol-32 glycerides; wherein the pharmaceutical composition contains no water, is in a liquid or a gel form, and the SN-38 is dissolved in the mixture of the excipients without precipitation.